TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00561210

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crucial
Description: Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sondalis HP
Description: Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
Study: NCT01509222

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized nutrition counseling
Study: NCT00587964

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: All patients would undergo craniotomy and the goal of surgery in all cases would be total removal of the metastases. The patient will initially receive premedication with 0.5- 1mg of Ativan orally prior to SRS procedure. Subsequently, the patient will have the stereotactic head ring placement under local anesthesia. A peripheral IV will be placed for administration of the intravenous contrast. Thin-section CT images will be obtained with intravenous contrast with head ring in place for the purpose of treatment planning.~A fusion program will be used to combine the recently obtained MRI images along with the CT scans. The target volume as well as the critical structures will be contoured. SRS would be delivered using either the Brain Lab or Radionics Radiosurgery planning and delivery system. Patients would receive a single treatment ranging from 15-22 GY.
Study: NCT01696201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate.
Study: NCT02870140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUPRAFLEX
Description: Percutaneous Coronary Intervention
Study: NCT00743067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1363089 (formerly XL880)
Description: GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1363089 (formerly XL880)
Description: GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally
Study: NCT04571242

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DTM Programming
Description: DTM-SCS programming
Study: NCT02870140

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE
Description: Percutaneous Coronary Intervention
Study: NCT01429480

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Ultrasound Guided Ilioinguinal/Iliohypogastric Block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Ultrasound Guided Posterior TAP Block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Study: NCT04209075

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biomebliss
Description: BiomeBliss is a commercially available powder containing prebiotic fiber (inulin and beta glucan), along with blueberry extract providing polyphenols.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biomebliss
Description: BiomeBliss is a commercially available powder containing prebiotic fiber (inulin and beta glucan), along with blueberry extract providing polyphenols.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is a commonly used antidiabetic medication, and the only oral medication approved for children and adolescents under 18 years old. Though reasonably effective, gastro-intestinal side effects are common (80% at initiation, and 10-30% after long term use). Metformin dosing at clinically recommended doses will be titrated per protocol during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is a commonly used antidiabetic medication, and the only oral medication approved for children and adolescents under 18 years old. Though reasonably effective, gastro-intestinal side effects are common (80% at initiation, and 10-30% after long term use). Metformin dosing at clinically recommended doses will be titrated per protocol during the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Comparator

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Comparator
Study: NCT01758354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pompe disease newborn screening
Description: DBS will be tested for acid alpha-glucosidase (GAA)activity. Newborns with low GAA activity will received a confirmatory blood sampling and clinical evaluation for the presence of cardiomyopathy.
Study: NCT01696487

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High oral Fructose challenge (150g per day for 28 days)
Study: NCT05140928

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dadiah Pudding
Description: Supplementation of Dadiah Pudding to pregnant women. One cup a day for 18-26 weeks of pregnancy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pudding without Dadiah
Description: Supplementation of Milk Pudding without dadiah to pregnant women. One cup a day for 18-26 weeks of pregnancy
Study: NCT03260166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinamide
Description: Drug: nicotinamide; Pharmaceutical form: tablet; Route of administration: oral
Study: NCT04571242

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional SCS programming
Description: Conventional SCS programming
Study: NCT01994603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-in or Opt-out testing
Description: Study participants will be offered a health screening onsite.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-in or Opt-out testing
Description: Study participants will be offered a health screening onsite.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Study participants will be invited to participate in a focus group discussion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Study participants will be invited to participate in a focus group discussion.
Study: NCT02475122

Intervention type: OTHER
Group type: OTHER
Intervention: azygos blood flow measurements by MRI
Study: NCT01939548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID until the Week 12 visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
Study: NCT01278134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus placebo
Description: 1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
Study: NCT02519426

Intervention type: PROCEDURE
Intervention: Mandibular third molar surgery
Description: Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.

Intervention type: PROCEDURE
Intervention: Mandibular third molar surgery
Description: Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.

Intervention type: PROCEDURE
Intervention: Mandibular third molar surgery
Description: Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.
Study: NCT00641602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: 30mg once daily
Study: NCT04532931

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care (Paracetamol)
Description: SOC - 2 tablets (1000 mg) to be taken 6-hourly as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Description: SOC plus artesunate-amodiaquine (ASAQ) - 2 tablets (200/540 mg artesunate/amodiaquine) daily for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Description: SOC plus pyronaridine-artesunate (PA) Weight 45 to \<65 kg: 3 tablets (540/180 mg pyronaridine/artesunate) daily for 3 days Weight ≥65 kg: 4 tablets (720/240 mg pyronaridine/artesunate) daily for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir plus Nitazoxanide
Description: SOC plus favipiravir plus nitazoxanide (FPV-NTZ) Favipiravir: 1600 mg 12-hourly for 1 day then 600 mg 12-hourly for 6 days Nitazoxanide: 2 tablets (1000 mg) 12-hourly for 7 days
Study: NCT02519426

Intervention type: PROCEDURE
Intervention: Mandibular third molar surgery
Description: Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.
Study: NCT04532931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/daclatasvir
Description: SOC plus sofosbuvir/daclatasvir (SOF/DCV)~1 tablet (400 mg/60 mg sofosbuvir/daclatasvir) daily for 7 days
Study: NCT01522378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123 iodine metaiodobenzylguanidine
Description: 10 millicurie (mCi) (370 MBq)
Study: NCT02519426

Intervention type: PROCEDURE
Intervention: Mandibular third molar surgery
Description: Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.

Intervention type: PROCEDURE
Intervention: Mandibular third molar surgery
Description: Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.
Study: NCT03824795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGB-BP-3
Description: MGB-BP-3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGB-BP-3
Description: MGB-BP-3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGB-BP-3
Description: MGB-BP-3
Study: NCT01135381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR-Enhanced Care
Description: Those randomized to e-Coach will receive initial coaching in the hospital and then will be called by the interactive voice response-supported (IVR) system at specified intervals after discharge for monitoring. Any red flags noted through the IVR monitoring system will be transmitted to the care transition coaches, who contact patients and coach them on how to address problems identified.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR-Enhanced Care
Description: Those randomized to e-Coach will receive initial coaching in the hospital and then will be called by the interactive voice response-supported (IVR) system at specified intervals after discharge for monitoring. Any red flags noted through the IVR monitoring system will be transmitted to the care transition coaches, who contact patients and coach them on how to address problems identified.
Study: NCT01408316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866
Description: Volunteers in part 1 of the study will receive two single dose 8 mg treatments of PX-866 (one each of crystalline PX-866 tablets and amorphous PX-866 capsules) in Periods A and B, separated by at least seven days. Volunteers in part 2 of the study will receive two single dose 6 mg treatments of PX-866 (crystalline PX-866 tablets administered in either fed or fasted state), in Periods C and D, separated by at least seven days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866
Description: Volunteers in part 1 of the study will receive two single dose 8 mg treatments of PX-866 (one each of crystalline PX-866 tablets and amorphous PX-866 capsules) in Periods A and B, separated by at least seven days. Volunteers in part 2 of the study will receive two single dose 6 mg treatments of PX-866 (crystalline PX-866 tablets administered in either fed or fasted state), in Periods C and D, separated by at least seven days.
Study: NCT03468114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Start
Description: Participant households will receive four visits over a 10 week period from health extension workers promoting safe food preparation, storage and feeding, and will be provided with products to support these practices (a bowl, spoon, cup, hand washing station, liquid soap dispenser).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participant households will receive 4 visits by health extension workers delivering standard care
Study: NCT02533050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: Patients treated wear a face mask during sleep which is connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airway and stimulate normal breathing.
Study: NCT03443362

Intervention type: PROCEDURE
Intervention: Punch Biopsy
Description: A 3 mm punch biopsy will be taken from lesional and non-lesional skin as a routine procedure.

Intervention type: PROCEDURE
Intervention: Punch Biopsy
Description: A 3 mm punch biopsy will be taken from lesional and non-lesional skin as a routine procedure.

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling
Study: NCT01129440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish
Description: Topical application of 0.25mL of fluoride varnish on each dental arch (upper and lower) at baseline and every 6 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Varnish
Description: Topical application of 0.25mL of fluoride varnish on each dental arch (upper and lower) at baseline and every 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glass Ionomer Sealant
Description: Fluoroaluminosilicate glass powder and polyacrylic acid liquid are mixed together in a capsule to form the glass ionomer sealant material.~After toothbrushing and conditioning dental surfaces with 20% polyacrylic acid for 10 seconds, pink-colored fluoride releasing glass ionomer dispensed from a capsule is applied to the occlusal (biting) surface of the molar.
Study: NCT02119455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Device
Description: Subjects receiving the OrthoAccel Aura device will be instructed to use the device for 20 minutes/day per the manufacturer's instructions during the study period.
Study: NCT02602275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurexan®
Description: There are two experimental conditions; in one condition participants receive Neurexan® and the second condition they receive Placebo for oral administration (three tablets) in a cross over design. In the experimantal arm participants will receive verum on DAY1/PERIOD 1 and will receive placebo on DAY2/PERIOD 2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There are two experimental conditions; in one condition participants receive Neurexan® and the second condition they receive Placebo for oral administration (three tablets) in a cross over design. In the comparator arm participants will receive placebo on DAY1/PERIOD 1 and will receive verum on DAY2/PERIOD 2.
Study: NCT01919866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transplantation of CD3/CD19 depleted stem cells
Study: NCT02184949

Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention

Intervention type: PROCEDURE
Intervention: Primary Percutaneous Coronary Intervention
Study: NCT06215781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fully digital workflow of prosthetic fixed dental crown
Description: The intervention that was administered was a full digital workflow. It includes an initial digital planning, an optical impression with intraoral scanner and a CAD-CAM milled zirconia crown. No analog materials were used.
Study: NCT00812383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System
Description: Angiomax (bivalirudin) versus standard anticoagulation with heparin during carotid artery stenting with distal protection clinical endpoint evaluation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System
Description: Angiomax (bivalirudin) versus standard anticoagulation with heparin during carotid artery stenting with distal protection clinical endpoint evaluation
Study: NCT01278134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000 mg bid orally, up to 24 weeks
Study: NCT05399940

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum PSA,Delta Neutrophil Index(DNI),WBC
Description: Urine culture, prostate volume

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum PSA,Delta Neutrophil Index(DNI),WBC
Description: Urine culture, prostate volume
Study: NCT01267565

Intervention type: OTHER
Group type: OTHER
Intervention: dosage of amylase
Description: 4 sets of aspirations on one day per inclusion in the intubated and ventilated patients group and 1 set of aspiration in the non intubated patients group

Intervention type: OTHER
Group type: OTHER
Intervention: dosage of amylase
Description: 4 sets of aspirations on one day per inclusion in the intubated and ventilated patients group and 1 set of aspiration in the non intubated patients group
Study: NCT06215781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined digital and conventional workflows of prosthetic fixed dental crown
Description: The intervention that was administered was a combined digital and traditional workflow. The initial planning was digital, then the impression was performed with analog impression material (silicones) and the final zirconia crown was CAD-CAM milled, with a digital procedure.
Study: NCT01278134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000 mg bid orally, up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg bid orally, up to 24 weeks
Study: NCT06215781

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fully conventional workflow of prosthetic fixed dental crown
Description: The intervention that was administered was a conventional workflow that doesn't provide any digital step. The impression was taken with analog material (silicones) and the final prosthesis was a metal-ceramic crown, realized on plaster cast.
Study: NCT00645775

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: IGOB131
Description: Comparison of 250 mg per day of Irvingia gabonensis to placebo
Study: NCT03685019

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Valgus Stress
Description: Valgus stress radiograph

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Varus stress
Description: Varus stress radiograph
Study: NCT01278134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg bid orally, up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
Study: NCT03685019

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 0 degree flexion radiograph
Description: 0 degree flexion radiograph

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 0 degree flexion radiograph
Description: 0 degree flexion radiograph
Study: NCT01278134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg bid orally, up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg bid orally, up to 24 weeks
Study: NCT03208023

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RESIPI Management Strategy
Description: a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical, Inc).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: No intervention
Study: NCT00700921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: 40mg po once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule, once daily